Ingevity - NGVT Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NGVT shares.
View NGVT analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price targets for Ingevity's shares. Their NGVT share price forecasts range from $73.00 to $87.00. On average, they expect the company's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $71.70 at the beginning of the year. Since then, NGVT shares have increased by 3.0% and is now trading at $73.84.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) issued its quarterly earnings results on Wednesday, November, 2nd. The company reported $2.09 EPS for the quarter, topping the consensus estimate of $1.72 by $0.37. The company earned $482 million during the quarter, compared to analysts' expectations of $428.39 million. Ingevity had a net margin of 13.90% and a trailing twelve-month return on equity of 36.37%.

Ingevity updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.65 billion-$1.70 billion, compared to the consensus revenue estimate of $1.60 billion.

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.03%), Vanguard Group Inc. (9.65%), State Street Corp (3.20%), LSV Asset Management (2.78%), Thrivent Financial for Lutherans (2.57%) and Massachusetts Financial Services Co. MA (2.49%). Insiders that own company stock include D Michael Wilson, Diane H Gulyas, Erik Spencer Ripple, Frederick J Lynch, John C Fortson, Michael P Smith, Richard Allen White Jr, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends.

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NGVT stock can currently be purchased for approximately $73.84.

Ingevity (NYSE:NGVT) has a market capitalization of $2.76 billion and generates $1.39 billion in revenue each year. The company earns $118.10 million in net income (profit) each year or $5.81 on an earnings per share basis.

The company employs 1,850 workers across the globe.

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for the company is www.ingevity.com. The company can be reached via phone at (844) 643-8489, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.